Hepatic Encephalopathy: all 225 studies

Page 2 of 3. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.

• Effect of Brief Dietary Intervention on Ammonia LevelsCompletedNCT05376488Not applicable
• Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic PatientsStatus unknownNCT05279586Early Phase 1
• Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic EncephalopathyStatus unknownNCT05229289Not applicable
• Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)Status unknownNCT05140837
• Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its ComplicationStatus unknownNCT05128305Phase 3
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisActive, not recruitingNCT05071716Phase 3
• Feasibility of an App-based Nutrition & Exercise Program in CirrhosisCompletedNCT05033327Not applicable
• Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver DiseaseTerminatedNCT04940416
• TReatment for ImmUne Mediated PathopHysiologyActive, not recruitingNCT04862221Phase 2
• Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic EncephalopathyTerminatedNCT04816916Phase 2
• Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic EncephalopathyCompletedNCT04787276Not applicable
• The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver CirrhosisCompletedNCT04771104Not applicable
• Microbial Resistance of Rifaximin in Hepatic EncephalopathyCompletedNCT04736836Phase 4
• Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal DiseasesCompletedNCT04698148
• HepQuant to Predict Hepatic Encephalopathy After TIPSWithdrawnNCT04664621Not applicable
• Cognitive Function of Alcoholic Compensated Liver CirrhosisCompletedNCT04557774
• Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)Status unknownNCT04436601Phase 4
• Flicker App for Minimal Hepatic EncephalopathyStatus unknownNCT04415294
• Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HEStatus unknownNCT04317222Not applicable
• Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion StentsCompletedNCT04315571Not applicable
• Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLFCompletedNCT04238416Phase 1
• CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated CirrhosisCompletedNCT04205396Not applicable
• Investigational Microbiota Restoration Therapeutic for Hepatic EncephalopathyTerminatedNCT04155099Phase 2
• Role of MRI in Detection of Minimal Hepatic EncephalopathyStatus unknownNCT04131205
• MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain FunctionWithdrawnNCT04128462Phase 3
• Rifamycin in Minimal Hepatic EncephalopathyCompletedNCT04082780Phase 2
• Transcranial Doppler Ultrasound and Minimal Hepatic EncephalopathyCompletedNCT04077125
• A Study of MHE in Patients With Liver DiseasesCompletedNCT04058327
• TIPS Plus Transvenous Obliteration for Gastric VaricesCompletedNCT04044248
• PEG3350 in ACLF With Hepatic EncephalopathyStatus unknownNCT03987893Phase 4
• Telehealth Intervention in CirrhoticsCompletedNCT03969186Not applicable
• Coenzyme Q10 and Meclofenoxate in Hepatic EncephalopathyStatus unknownNCT03961087Not applicable
• The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic EncephalopathyStatus unknownNCT03825848Not applicable
• Minimal Hepatic Encephalopathy in Hereditary Hemorrhagic TelangiectasianCompletedNCT03586115
• HEAL STUDY (Hepatic Encephalopathy and Albumin Study)CompletedNCT03585257Phase 2
• Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD TrialCompletedNCT03493204Not applicable
• Fecal Transplant for Hepatic EncephalopathyCompletedNCT03439982Phase 1/2
• Fecal Microbiota Transplant as Treatment of Hepatic EncephalopathyActive, not recruitingNCT03420482Phase 2
• Diet Management on Hepatic Encephalopathy of Patients With Variceal Bleeding After Intrahepatic Portosystemic Shunt CreationStatus unknownNCT03372499Not applicable
• Plasma Free Amino Acids in Patients With Hepatic EncephalopathyStatus unknownNCT03306498
• Oral Fecal Transplant in CirrhosisCompletedNCT03152188Phase 1
• High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.WithdrawnNCT03115697Not applicable
• PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic EncephalopathyStatus unknownNCT03100513Phase 4
• Low-dose Rifaximin in the Treatment of Covert Hepatic EncephalopathyCompletedNCT03077217Phase 4
• Timing of Acute Palliative Care Consultation in Critically Ill PatientsStatus unknownNCT02858778Not applicable
• Reversibility of Minimal Hepatic Encephalopathy Following Liver TransplantationCompletedNCT02767622
• The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP).Status unknownNCT02692430
• Fecal Transplant in Recurrent Hepatic EncephalopathyCompletedNCT02636647Phase 1
• Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTanCompletedNCT02613858
• Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot StudyCompletedNCT02520817
• Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)CompletedNCT02488993
• Metformin Experience on Minimal Hepatic EncephalopathyStatus unknownNCT02470546Phase 4
• Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic EncephalopathyStatus unknownNCT02464124Phase 2/3
• Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic PatientsStatus unknownNCT02427906
• Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic EncephalopathyStatus unknownNCT02401490Phase 4
• The Effects of Nitazoxanide in Hepatic EncephalopathyStatus unknownNCT02334163Phase 2
• Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot StudyCompletedNCT02255617Phase 1/2
• Quantitative Determination of Brain Water Content in Patients During and After Hepatic EncepalopathyStatus unknownNCT02177708
• Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal BleedingCompletedNCT02158182Phase 4
• Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Hepatic EncephalopathyCompletedNCT02156232Not applicable
• iPod Games in Hepatic EncephalopathyCompletedNCT02154282Not applicable
• A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal FailureWithdrawnNCT02086825Phase 3
• Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy OutcomeCompletedNCT02083367
• Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRSWithdrawnNCT02048969Phase 1/2
• Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.Status unknownNCT02028429Phase 1/2
• Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)TerminatedNCT02026609
• Branched Chain Aminoacid Supplementation in Patients With Liver CirrhosisCompletedNCT02023229Phase 4
• Fructans, Lactitol and Lactose in Minimal Hepatic EncephalopathyCompletedNCT02022137Not applicable
• Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic EncephalopathyCompletedNCT02019784Phase 4
• Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic PatientsCompletedNCT02017119Phase 2
• Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)WithdrawnNCT01923376Not applicable
• Effect of Music on Attention and Prospective Memory in Hepatic EncephalopathyWithdrawnNCT01882855
• Neuromonitoring of Hepatic EncephalopathyCompletedNCT01878305
• Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartateCompletedNCT01847651Phase 4
• Factors Associated With End Stage Liver DiseaseTerminatedNCT01846819
• The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.TerminatedNCT01846806Not applicable
• Quality of Life and Nutritional Improvements in Cirrhotic PatientsTerminatedNCT01842113Phase 4
• ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional StudyStatus unknownNCT01798329Phase 3
• The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in CirrhosisWithdrawnNCT01777971
• Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time MeasurementCompletedNCT01773538Not applicable
• L-ornithine L-aspartate in Overt Hepatic EncephalopathyCompletedNCT01722578Phase 4
• Bioelectrical Impedance Vector Analysis in Cirrhotic PatientsCompletedNCT01603953
• Cerebrovascular Autoregulation During and After Liver TransplantationStatus unknownNCT01597102
• Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic EncephalopathyCompletedNCT01559519Phase 4
• Effect of Tolvaptan on Cognitive Function in CirrhosisCompletedNCT01556646Phase 3
• Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive CareCompletedNCT01494064
• S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHECompletedNCT01446523Not applicable
• Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance ImagingStatus unknownNCT01434056
• Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in CirrhoticsStatus unknownNCT01356121Phase 4
• Acetyl-L-Carnitine In Severe Hepatic EncephalopathyCompletedNCT01223768Not applicable
• Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic EncephalopathyCompletedNCT01223742Not applicable
• Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized TrialCompletedNCT01218568Not applicable
• Secondary Prophylaxis of Hepatic Encephalopathy in CirrhosisStatus unknownNCT01178372Phase 4
• Primary Prophylaxis of Hepatic Encephalopathy in Patients With CirrhosisStatus unknownNCT01175538Phase 4
• Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE)CompletedNCT01151475
• Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic EncephalopathyTerminatedNCT01113567Not applicable
• Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic PreparationCompletedNCT01110447Phase 2/3
• Cerebrovascular Reactivity in Hepatic EncephalopathyCompletedNCT01099293
• Comparison Between Erythromycin and Neomycin Treatment of Hepatic EncephalopathyStatus unknownNCT01097811Not applicable
• Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortalCompletedNCT01059396Phase 4

← Hepatic Encephalopathy overview